Patient privacy focus of Amgen suit

January 9, 2008

Two former employees with the California biotech company Amgen Inc. allege the company persuaded sales people to access patient records to boost sales.

The employees allege Amgen officials persuaded them to access patient records and sometimes pose of medical office personnel to influence the prescription of the arthritis and psoriasis drug Enbrel, the Los Angeles Times reported Wednesday.

Federal law prohibits unauthorized access to patient's medical information. Drug companies are also prohibited from marketing off-label uses, though doctors may prescribe drugs for any reason.

A former FDA lawyer said off-label marketing "is if you have a drug for colon cancer that you promote for brain cancer" while another advocate said Amgen violated FDA regulations by persuading patients to seek the Enbrel for milder forms of the diseases it was approved treat.

Copyright 2008 by United Press International

Explore further: Out-of-pocket costs often keep pricey new cholesterol drugs out of reach, study finds

Related Stories

Out-of-pocket costs often keep pricey new cholesterol drugs out of reach, study finds

October 4, 2017
Access to powerful new cholesterol-lowering drugs is so tightly controlled and patients' out-of-pocket costs are so high that fewer than a third of people whose doctors prescribe the drugs get them, a new study found.

New 'biologic' drug may help severe asthma

September 7, 2017
(HealthDay)—A "biologic" drug in development to treat severe asthma reduces the rate of serious attacks by about two-thirds compared to a placebo drug, according to preliminary research findings.

Biologics—the pricey drugs transforming medicine

July 25, 2017
In a factory just outside San Francisco, there's an upright stainless steel vat the size of a small car, and it's got something swirling inside.

FDA approves first biosimilar drug for cancer

September 15, 2017
(HealthDay)—The first biosimilar drug to treat cancer has been approved by the U.S. Food and Drug Administration.

FDA panel backs Amgen cholesterol drug for some patients (Update)

June 10, 2015
Federal health advisers said Wednesday that a highly-anticipated cholesterol-lowering drug from Amgen Inc. should be approved for patients with dangerously high levels of the artery-clogging substance.

Amgen may buy cancer drug maker Onyx for $10.5B

August 25, 2013
Biotech drugmaker Amgen is reportedly close to buying cancer drug maker Onyx Pharmaceuticals for about $10.5 billion.

Recommended for you

Drug therapy from lethal bacteria could reduce kidney transplant rejection

August 3, 2017
An experimental treatment derived from a potentially deadly microorganism may provide lifesaving help for kidney transplant patients, according to an international study led by investigators at Cedars-Sinai.

Exploring the potential of human echolocation

June 25, 2017
People who are visually impaired will often use a cane to feel out their surroundings. With training and practice, people can learn to use the pitch, loudness and timbre of echoes from the cane or other sounds to navigate ...

Team eradicates hepatitis C in 10 patients following lifesaving transplants from infected donors

April 30, 2017
Ten patients at Penn Medicine have been cured of the Hepatitis C virus (HCV) following lifesaving kidney transplants from deceased donors who were infected with the disease. The findings point to new strategies for increasing ...

'bench to bedside to bench': Scientists call for closer basic-clinical collaborations

March 24, 2017
In the era of genome sequencing, it's time to update the old "bench-to-bedside" shorthand for how basic research discoveries inform clinical practice, researchers from The Jackson Laboratory (JAX), National Human Genome Research ...

The ethics of tracking athletes' biometric data

January 18, 2017
(Medical Xpress)—Whether it is a FitBit or a heart rate monitor, biometric technologies have become household devices. Professional sports leagues use some of the most technologically advanced biodata tracking systems to ...

Financial ties between researchers and drug industry linked to positive trial results

January 18, 2017
Financial ties between researchers and companies that make the drugs they are studying are independently associated with positive trial results, suggesting bias in the evidence base, concludes a study published by The BMJ ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.